Inability of Pneumocystis organisms to incorporate bromodeoxyuridine suggests the absence of a salvage pathway for thymidine

Microbiology

Volumn 150, Issue 5, 2004, Pages 1179-1182

  Vestereng, Vibeke H ^b   Kovacs, Joseph A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; THYMIDINE; THYMIDYLATE SYNTHASE;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME INHIBITION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PNEUMOCYSTIS; PRIORITY JOURNAL; RAT;

PNEUMOCYSTIS;

EID: 2942564042     PISSN: 13500872     EISSN: None     Source Type: Journal    
DOI: 10.1099/mic.0.26890-0     Document Type: Article

References (35)

1. Anderson, A. C., Perry, K. M., Freymann, D. M. & Stroud, R. M. (2000). The crystal structure of thymidylate synthase from Pneumocystis carinii reveals a fungal insert important for drug design. J Mol Biol 297, 645-657.
2. Angus, C. W., Tu, A., Vogel, P., Qin, M. & Kovacs, J. A. (1996). Expression of variants of the major surface glycoprotein of Pneumocystis carinii. J Exp Med 183, 1229-1234.
3. Danenberg, P. V., Malli, H. & Swenson, S. (1999). Thymidylate synthase inhibitors. Semin Oncol 26, 621-631.
4. Dolbeare, F. (1995a). Bromodeoxyuridine: a diagnostic tool in biology and medicine, part II: oncology, chemotherapy and carcinogenesis. Histochem J 27, 923-964.
5. Dolbeare, F. (1995b). Bromodeoxyuridine: a diagnostic tool in biology and medicine, part I: historical perspectives, histochemical methods and cell kinetics. Histochem J 27, 339-369.
6. Dolbeare, F. (1996). Bromodeoxyuridine: a diagnostic tool in biology and medicine, part III. Proliferation in normal, injured and diseased tissue, growth factors, differentiation, DNA replication sites and in situ hybridization. Histochem J 28, 531-575.
7. Edman, J. C., Kovacs, J. A., Masur, H., Santi, D. V., Elwood, H. J. & Sogin, M. L. (1988). Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 334, 519-522.
8. Edman, U., Edman, J. C., Lundgren, B. & Santi, D. V. (1989). Isolation and expression of the Pneumocystis carinii thymidylate synthase gene. Proc Natl Acad Sci U S A 86, 6503-6507.
9. + T cells. Proc Natl Acad Sci U S A 96, 8597-8602.
10. Gutierrez, J. C., Callejas, S., Borniquel, S. & Martin-Gonzalez, A. (2000). DNA methylation in ciliates: implications in differentiation processes. Int Microbiol 3, 139-146.
11. Helweg-Larsen, J., Benfield, T. L., Eugen-Olsen, J., Lundgren, J. D. & Lundgren, B. (1999). Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 354, 1347-1351.
12. Hodson, J. A., Bailis, J. M. & Forsburg, S. L. (2003). Efficient labeling of fission yeast Schizosaccharomyces pombe with thymidine and BUdR. Nucleic Acids Res 31, e134.
13. Hughes, W. T. (1998). Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis 27, 191-204.
14. Hughes, W., Leoung, G., Kramer, F. & 14 other authors (1993). Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 328, 1521-1527.
15. Jarroll, E. L., Manning, P., Berrada, A., Hare, D. & Lindmark, D. G. (1989). Biochemistry and metabolism of Giardia. J Protozool 36, 190-197.
16. Jiang, L., Lee, P. C., White, J. & Rathod, P. K. (2000). Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum. Antimicrob Agents Chemother 44, 1047-1050.
17. Kazanjian, P., Armstrong, W., Hossler, P. A., Burman, W., Richardson, J., Lee, C. H., Crane, L., Katz, J. & Meshnick, S. R. (2000). Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis 182, 551-557.
18. Kellett, M., Potten, C. S. & Rew, D. A. (1992). A comparison of in vivo cell proliferation measurements in the intestine of mouse and man. Epithelial Cell Biol 1, 147-155.
19. Kovacs, J. A. & Masur, H. (2000). Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 342, 1416-1429.
20. Kovacs, J. A., Halpern, J. L., Swan, J. C., Moss, J., Parrillo, J. E. & Masur, H. (1988). Identification of antigens and antibodies specific for Pneumocystis carinii. J Immunol 140, 2023-2031.
21. Kovacs, J. A., Allegra, C. J. & Masur, H. (1990). Characterization of dihydrofolate reductase of Pneumocystis carinii and Toxoplasma gondii. Exp Parasitol 71, 60-68.
22. Kovacs, J. A., Gill, V. J., Meshnick, S. & Masur, H. (2001a). New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA (J Am Med Assoc) 286, 2450-2460.
23. Kovacs, J. A., Lempicki, R. A., Sidorov, I. A. & 17 other authors (2001b). Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med 194, 1731-1741.
24. Ma, L., Borio, L., Masur, H. & Kovacs, J. A. (1999). Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis 180, 1969-1978.
25. Martinez, A. & Kovacs, J. A. (1993). Development and characterization of a rapid screening assay for identifying antipneumocystis agents. Antimicrob Agents Chemother 37, 1674-1678.
26. Mei, Q., Wang, Q., Chen, Y., Liu, Y., Fan, W. & Li, P. (1995). Experimental and clinical study on pneumocystosis. IV. Use of a 4D7 monoclonal antibody to detect Pneumocystis carinii by immunoperoxidase staining. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 13, 130-133 (in Chinese).
27. Navin, T. R., Beard, C. B., Huang, L. & 7 other authors (2001). Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P. carinii pneumonia in patients with HIV-1: a prospective study. Lancet 358, 545-549.
28. Phair, J., Munoz, A., Detels, R., Kaslow, R., Rinaldo, C. & Saah, A. (1990). The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 322, 161-165.
29. Roblot, F., Godet, C., Le Moal, G. & 9 other authors (2002). Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 21, 523-531.
30. Santi, D. V., Edman, U., Minkin, S. & Greene, P. J. (1991). Purification and characterization of recombinant Pneumocystis carinii thymidylate synthase. Protein Expr Purif 2, 350-354.
31. Sattler, F. R., Cowan, R., Nielsen, D. M. & Ruskin, J. (1988). Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med 109, 280-287.
32. Sherman, I. W. (1979). Biochemistry of Plasmodium (malarial parasites). Microbiol Rev 43, 453-495.
33. Vasconcelles, M. J., Bernardo, M. V., King, C., Weller, E. A. & Antin, J. H. (2000). Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 6, 35-43.
34. Vernis, L., Piskur, J. & Diffley, J. F. (2003). Reconstitution of an efficient thymidine salvage pathway in Saccharomyces cerevisiae. Nucleic Acids Res 31, e120.
35. Walzer, P. D., Runck, J., Steele, P., White, M., Linke, M. J. & Sidman, C. L. (1997). Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs. Antimicrob Agents Chemother 41, 251-258.